2023 Strategic Priorities
- Diagnostic Imaging: increase EluciremTM sales
and strengthen international positions
- Interventional Imaging: prioritise Lipiodol
sales with the development of innovative indications
- Artificial Intelligence: execution of the
roadmap for the emergence of a major AI player dedicated to medical
imaging in oncology
Villepinte, 16 January 2023:
Guerbet (FR0000032526 GBT), a global specialist in contrast agents
and solutions for medical imaging has announced its strategic
priorities for 2023 in a complex international environment
characterised by persistent inflationary pressures and the
revelation of new business opportunities for products listed in
developing markets.
For several quarters, the Group has operated in
an environment marked by a favorable trend in the contrast agent
market, where structural volume growth seems to be accompanied by
positive price effects over time, particularly in the face of
difficult purchasing conditions (notably for iodine).
In this demanding yet promising context, Guerbet
intends to capitalise on its core target activities and established
positions, allocate its resources to developing recognised products
adapted to the immediate needs of professionals, and mobilising its
teams around three main ambitions:
Diagnostic Imaging: strategic
reinforcement
In this market where Guerbet generates nearly
90% of its revenue, 2023 will mark an important milestone with the
market release in the United States of the first batches of the
brand new EluciremTM, which is attracting strong interest from the
scientific community and ordering parties. In Europe, the European
Medicines Agency (EMA) review is expected in the second half of the
year. In addition to ElucirmTM, the Group intends to strengthen its
solid positions in diagnostic imaging (world’s number 2 in the MRI,
number 4 in X-Rays) by supporting customer needs as close as
possible with its comprehensive, interconnected offering, including
contrast agents, injection systems, and digital solutions.
Interventional Imaging: resources
allocated to the growth of established products
- Commercial development and expansion of applications of
Lipiodol
Established for 40 years as a standard in the
treatment of liver cancer, Lipiodol also has a strong foothold in
other areas – including vascular embolization, lymphography, and
hysterosalpingography (HSG) – which now account for a significant
portion of sales volumes and future growth. The potential for
development of new innovative indications appears to be
significant, particularly in the treatment of musculoskeletal
disorders, venous diseases, and post-surgery and cancer disorders.
Research and development efforts will thus be accelerated in order
to explore new applications for Lipiodol.
- Microcatheter activity divestment plan
In connection with the evolution of its strategy
aimed at leveraging key assets, Guerbet is planning the gradual
divestment of its microcatheter activities historically housed
within Accurate Medical Therapeutics. Since its acquisition in
2018, the microcatheters portfolio has been significantly expanded,
now containing 38 references across the two SeQure® and DraKon™
microcatheter ranges for peripheral embolization procedures. This
activity has is not significant revenue contributor at the Group
level and currently requires specialised, reinforced sales teams
and significant investments to achieve its full commercial
potential. These necessities are no longer in line with the Group’s
development strategy. Guerbet also plans to divest the Occlugel
technology acquired in 2018, including several ranges of
microspheres for use in embolization.
Artificial Intelligence: acceleration of
the roadmap
Following the termination of its collaboration
with Merative (formerly IBM Watson Health) announced in October
2022, Guerbet has regained all the necessary latitude to roll out
the commercial strategy while maintaining full ownership of the
developed assets (application software source codes and algorithms)
and their intellectual property. Very promising results were
already obtained in 2022 in the detection of liver damage and
prostate cancer. The commercial development of the solutions will
benefit from the licensing agreement expected to be signed in the
first half of 2023 with Intrasense following Guerbet’s acquisition
of a stake in the company announced on 11 January. Guerbet
ultimately aims to enable the development of a major player in
artificial intelligence applied to medical imaging in oncology.
Upcoming events:
Publication of 2022 full-year
revenueFebruary 9, 2023, after trading
About GuerbetAt Guerbet, we
build lasting relationships so that we enable people to live
better. That is our purpose. We are a global leader in medical
imaging, offering a comprehensive range of pharmaceutical products,
medical devices, and digital and AI solutions for diagnostic and
interventional imaging. As pioneers in contrast products for 95
years, with more than 2,600 employees worldwide, we continuously
innovate and devote 8%-10% of our revenue to research and
development in five centers in France, Israel, and the United
States. Guerbet (GBT) is listed on Euronext Paris (segment B – mid
caps) and generated €732 million in revenue in 2021. For more
information, please visit www.guerbet.com.
About Gadopiclenol
Gadopiclenol, initially invented by Guerbet with subsequent
contribution of Bracco intellectual property, is a new macrocyclic
gadolinium-based contrast agent (GBCA) with high relaxivity. The
efficacy and safety of Gadopiclenol have been evaluated in MRI of
the Central Nervous System, head and neck, thorax, abdomen, pelvis
and musculoskeletal system (refer to the approved USPI for full
information).
Details on Phase III clinical trials are available on
www.ClinicalTrials.gov :
• Efficacy and Safety of Gadopiclenol for Central Nervous System
(CNS) Magnetic Resonance Imaging (MRI) Full Text View -
ClinicalTrials.gov
• Efficacy and Safety of Gadopiclenol for Body Magnetic
Resonance Imaging (MRI) - Full Text View - ClinicalTrials.gov
Gadopiclenol is currently in the process of examination by the
European Medicines Agency.
Forward-looking
statements
This press release may contain statements of a forward-looking
nature, based on assumptions and predictions made by the management
of the Guerbet group. Various known and unknown risks,
uncertainties and other factors could lead to marked differences
between the future results, financial situation, development and
performances of the company, and the estimates made here. These
factors include those mentioned in the public reports of Guerbet,
available on its website www.guerbet.com.The company assumes no
responsibility whatsoever in relation to the updating of these
forward-looking statements, or how they correspond to future events
or developments.
Contacts:
Guerbet Jérôme Estampes, Chief Financial
Officer +33.1.45.91.50.00 / jerome.estampes@guerbet.comClaire
Lauvernier, Communications Director +33.6.79.52.11.88 /
claire.lauvernier@guerbet.com
Actifin Marianne Py,
Financial Communications + 33.1.56.88.11.25 /
mpy@actifin.frJennifer Jullia, Press +33.1.56.88.11.19 /
jjullia@actifin.fr
- Press Release - Accurate-2023_01_16
Guerbet (EU:GBT)
Graphique Historique de l'Action
De Mar 2023 à Mar 2023
Guerbet (EU:GBT)
Graphique Historique de l'Action
De Mar 2022 à Mar 2023
